| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
ACRS
Aclaris Therapeutics
|
Oct 28, 2026 | BUY |
Strong Buy
+155.5% avg upside
16 analysts
|
$9.00
126.64% Upside
|
-13.1% | Β· |
|
TSE:MSCL
Satellos Bioscience
|
Oct 08, 2026 | BUY |
Strong Buy
+223.2% avg upside
9 analysts
|
$33.51
251.40% Upside
|
-11.8% | Β· |
|
ATHE
Alterity Therapeutics
|
Oct 05, 2026 | BUY |
Strong Buy
+372.6% avg upside
8 analysts
|
$15.00
594.47% Upside
|
-41.9% | Β· |
|
IMNM
Immunome
|
Aug 12, 2026 | BUY |
Strong Buy
+81.9% avg upside
19 analysts
|
$36.00
97.69% Upside
|
-38.6% | Β· |
|
LBRX
LB Pharmaceuticals, Inc.
|
Aug 12, 2026 | BUY |
Strong Buy
+47.7% avg upside
11 analysts
|
$45.00
13.39% Upside
|
-11.2% | Β· |
|
PEPG
PepGen Inc.
|
Aug 06, 2026 | BUY |
Strong Buy
+349.9% avg upside
9 analysts
|
$11.00
366.09% Upside
|
+58.9% | Β· |
|
DSGN
Design Therapeutics
|
Aug 04, 2026 | BUY |
Strong Buy
+66.1% avg upside
9 analysts
|
$22.00
106.06% Upside
|
-28.3% | Β· |
|
MPLT
MapLight Therapeutics, Inc.
|
Jul 28, 2026 | BUY |
Strong Buy
+288.0% avg upside
14 analysts
|
$25.00
229.73% Upside
|
-50.1% | Β· |
|
HIT
Health In Tech, Inc. Class A
|
Apr 10, 2026 | BUY |
Strong Buy
+354.8% avg upside
3 analysts
|
β | -71.6% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.